Efficacy and Safety of Lebrikizumab in Adults With Moderate to Severe Atopic Dermatitis

This phase 2b, placebo-controlled, randomized clinical trial evaluates the efficacy and safety of lebrikizumab, a novel, high-affinity, monoclonal antibody targeting interleukin (IL) –13 that selectively prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex, in adults with moderate to severe atopic dermatitis.
Source: JAMA Dermatology - Category: Dermatology Source Type: research